Search Results - "Hinder, V."

2124 Factors associated with community use of adjuvant chemotherapy for stage III colon cancer - results from a national cohort study by Jackson, C, Hinder, V, Sharples, K, Jeffery, M, Murray, M, Findlay, M

Get full text

A randomised phase IIb trial to assess the efficacy of ReCharge ice cream in preventing chemotherapy-induced diarrhoea by Perez, D., Sharples, K. J., Broom, R., Jeffery, M., Proctor, J., Hinder, V., Pollard, S., Edwards, J., Simpson, A., Scott, J., Benge, S., Krissansen, G., Geursen, A., Palmano, K., MacGibbon, A., Keefe, D., Findlay, M.

“…Purpose Chemotherapy-induced diarrhoea (CID) has a significant impact. A medicinal food product (ReCharge) containing iron-saturated lactoferrin and anhydrous…”
Get full text

A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II by Harvey, V.J., Sharples, K.J., Isaacs, R.J., Jameson, M.B., Jeffery, G.M., McLaren, B.R., Pollard, S., Riley, G.A., Simpson, A.B., Hinder, V.A., Scott, J.N., Dzhelali, M.V., Findlay, M.P.

“…Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have non-overlapping toxic effects and synergy pre-clinically. We…”
Get full text

The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study by Ratnakumaran, R., Hinder, V., Brand, D.H., Staffurth, J., Hall, E., van As, N., Tree, A.

“…Acute gastrointestinal (GI) and genitourinary (GU) toxicity after prostate radiotherapy (RT) has been shown to be associated with late toxicity with 3D…”
Get full text

OC-0105 PROMPTS RCT of screening MRI for spinal cord compression in prostate cancer (ISRCTN74112318) by Dearnaley, D., Hinder, V., Hijab, A., Horan, G., Srihari, N., Rich, P., Houston, G., Henry, A., Gibbs, S., Venkitaraman, R., Cruickshank, C., Hassan, S., Mason, M., Pedley, I., Payne, H., Brock, S., Wade, R., Robinson, A., Din, O., Lees, K., Murray, J., Parker, C., Griffin, C., Sohaib, A., Hall, E.

Get full text

Patient Reported Acute Toxicity in PACE-B, an International Phase III Randomised Controlled Trial Comparing Stereotactic Body Radiotherapy to Conventionally Fractionated or Moderately Hypofractionated Radiotherapy (CFMHRT) for Localised Prostate Cancer by Brand, D.H., Tree, A., Ostler, P., van der Voet, H., Loblaw, D.A., Chu, W., Ford, D., Tolan, S., Jain, S., Martin, A., Staffurth, J., Brown, S., Burnett, S., Duffton, A., Griffin, C., Hinder, V., Morrison, K., Naismith, O., Hall, E., van As, N.

Get full text

The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma by Sahi, C., Knox, J. J., Hinder, V., Deva, S., Cole, D., Clemons, M., Broom, R. J.

“…Abstract only e16145 Background: Bone metastases (BM) from renal cell carcinoma (RCC) are common and associated with poor outcomes. While the multi-tyrosine…”
Get full text

A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II by Harvey, V J, Sharples, K J, Isaacs, R J, Jameson, M B, Jeffery, G M, McLaren, B R, Pollard, S, Riley, G A, Simpson, A B, Hinder, V A, Scott, J N, Dzhelali, M V, Findlay, M P

“…Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have non-overlapping toxic effects and synergy pre-clinically. We…”
Get full text

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study by Jackson, Christopher G C A, Sharples, Katrina, Thompson, Paul I, O'Donnell, Anne, Robinson, Bridget Anne, Perez, David J, Adams, Jacqui, Isaacs, Richard, Deva, Sanjeev, Hinder, Victoria A, Findlay, Michael P

“…Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two…”
Get full text